Clinical and bacteriologic response to single-dose or multiple-dose ciprofloxacin therapy in patients infected with nalidixic acid-resistant strains of <i>V</i>. <i>cholerae</i> O1.

<p>Values are median (25^th–75^th centile) unless noted.</p><p>* Based on weight discharge</p><p>Clinical and bacteriologic response to single-dose or multiple-dose ciprofloxacin therapy in patients infected with nalidixic acid-resistant strains of <i>V</i>. <i>cholerae</i> O1.</p

Randomized controlled trials from which 161 adult patients infected with <i>V</i>. <i>cholerae</i> O1;treated with ciprofloxacin and completed 5day study were included in this analysis.

<p>There were 580 patients in total in these four studies, of whom 161 (28%) were infected with <i>V</i>.<i>cholerae</i> O1; treated with ciprofloxacin and completed 5 day study</p><p>Randomized controlled trials from which 161 adult patients infected with <i>V</i>. <i>cholerae</i> O1;treated with ciprofloxacin and completed 5day study were included in this analysis.</p

Nalidixic acid and ciprofloxacin MIC⁵⁰and MIC⁹⁰ of 275 isolates of <i>V cholerae</i> O1 by year and source of strains obtained.

<p>Values are (μg/ml)</p><p>CT–Clinical trial; CLS–Clinical Laboratory Services, icddr,b</p><p>Nalidixic acid and ciprofloxacin MIC⁵⁰and MIC⁹⁰ of 275 isolates of <i>V cholerae</i> O1 by year and source of strains obtained.</p

Admission characteristics and response to ciprofloxacin therapy in 161 patients infected with nalidixic acid-susceptible and nalidixic acid-resistant strains of <i>V</i>. <i>cholerae</i> O1.

<p>Values are median (25^th, 75^th centiles) unless noted</p><p>* Based on disc-diffusion method</p><p>^‡ Based on discharge weight</p><p>Admission characteristics and response to ciprofloxacin therapy in 161 patients infected with nalidixic acid-susceptible and nalidixic acid-resistant strains of <i>V</i>. <i>cholerae</i> O1.</p

Clinical and bacteriologic response to single-dose or multiple-dose ciprofloxacin therapy in patients infected with nalidixic acid-resistant strains of <i>V</i>. <i>cholerae</i> O1.

<p>Values are median (25^th–75^th centile) unless noted.</p><p>* Based on weight discharge</p><p>Clinical and bacteriologic response to single-dose or multiple-dose ciprofloxacin therapy in patients infected with nalidixic acid-resistant strains of <i>V</i>. <i>cholerae</i> O1.</p

Clinical and bacteriologic response to single-dose or multiple-dose ciprofloxacin therapy in patients infected with nalidixic acid-susceptible strains of <i>V</i>. <i>cholerae</i> O1.

<p>Values are median (25^th–75^th centiles) unless noted</p><p>* Based on discharge weight</p><p>Clinical and bacteriologic response to single-dose or multiple-dose ciprofloxacin therapy in patients infected with nalidixic acid-susceptible strains of <i>V</i>. <i>cholerae</i> O1.</p

Odds of asymptomatic infection in high & medium incidence clusters.

<p>OR, odds ratio; 95% CI, 95% confidence interval;</p>a<p>Missing data in demographic and bednet survey;</p>b<p>Not selected into final multivariate model based on higher than 10% Type I error on LR test.</p

Box-plots of hemoglobin in pregnant and non-pregnant women with or without asymptomatic malaria.

<p>Box-plots represent the median and interquartile range of hemoglobin concentration. Panel <b>A</b> shows values in non-pregnant (n = 444) and pregnant (n = 495), <b>B</b>, malaria negative (n = 926) and malaria positive (n = 13), and <b>C</b>, the interaction of pregnancy and malaria indicating the lowest hemoglobin concentration in malaria-positive pregnant women (n = 10) compared with malaria-negative non-pregnant (n = 441) or pregnant (n = 485) women or malaria-positive non-pregnant women (n = 3). (Statistical significance by non-parametric Kruskal-Wallis equality of populations test)</p

Description of the study participants.

<p>Description of the study participants.</p

Prevalence of asymptomatic malaria infection by demographics.

<p>Prevalence of asymptomatic malaria infection by demographics.</p